Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Sunday, September 26, 2021
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
Wednesday, September 15, 2021
Hua and Sinopharm Announced Supply Chain Strategic Cooperation
Thursday, August 19, 2021
Hua Medicine Announces 2021 Interim Results
Friday, April 23, 2021
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally
Friday, March 19, 2021
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission
Friday, December 18, 2020
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial
Wednesday, October 14, 2020
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin
Monday, August 17, 2020
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China
Wednesday, July 1, 2020
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin
Thursday, June 18, 2020
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: